The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Melatonin in Alzheimer’s Disease
Open accessAbstract
Alzheimer’s disease (AD), an age-related neurodegenerative disorder with progressive cognition deficit, is characterized by extracellular senile plaques (SP) of aggregated β-amyloid (Aβ) and intracellular neurofibrillary tangles, mainly containing the hyperphosphorylated microtubule-associated protein tau. Multiple factors contribute to the etiology of AD in terms of initiation and progression. Melatonin is an endogenously produced hormone in the brain and decreases during aging and in patients with AD. Data from clinical trials indicate that melatonin supplementation improves sleep, ameliorates sundowning and slows down the progression of cognitive impairment in AD patients. Melatonin efficiently protects neuronal cells from Aβ-mediated toxicity via antioxidant and anti-amyloid properties. It not only inhibits Aβ generation, but also arrests the formation of amyloid fibrils by a structure-dependent interaction with Aβ. Our studies have demonstrated that melatonin efficiently attenuates Alzheimer-like tau hyperphosphorylation. Although the exact mechanism is still not fully understood, a direct regulatory influence of melatonin on the activities of protein kinases and protein phosphatases is proposed. Additionally, melatonin also plays a role in protecting the cholinergic system and in anti-inflammation. The aim of this review is to stimulate interest in melatonin as a potentially useful agent in the prevention and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Microglia and neuroinflammation: a pathological perspective
Streit (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-14 · Cited by 1,039
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Combadière, C., Feumi, C., Raoul, W., Keller, N., Rodéro, M., Pézard, A., Lavalette, S., Houssier, M., Jonet, L., Picard, E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31692 · Cited by 618 · cited 1×
“A common factor in AD pathogeny is the over activation of microglia with the consequent over expression of proinflammatory cytokines [128–130].”
BackgroundTau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594
Hanger, D. P., Byers, H. L., Wray, S., Leung, K.-Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A., & Anderton, B. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703269200 · Cited by 455
Post-translational modifications of tau protein in Alzheimer’s disease
Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437
Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain
Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., & Ihara, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41890-x · Cited by 430
Research works printed but not linked: 132
- Lars, 2011, Amyloid-β and tau—A toxic pas de deux in Alzheimer’s disease, Nat. Rev. Neurosci, 12, 67, 10.1038/nrn2967 · DOI · Paper page
- Mustapic, 2012, Alzheimer’s disease and type 2 diabetes: The association study of polymorphisms in tumor necrosis factor-alpha and apolipoprotein E genes, Metab. Brain Dis, 27, 507, 10.1007/s11011-012-9310-1 · DOI
- Ajala, T., Rafi, J., Wray, R., Whitehead, M.W., and Zaidi, J. (2009). There may be a link between intrahepatic cholestasis of pregnancy and familial combined hyperlipidaemia: A case report. Cases J., 2. · DOI
- Leszek, 2012, Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer’s disease, J. Neurol. Sci, 323, 25, 10.1016/j.jns.2012.09.010 · DOI
- Rocchi, 2012, NMR metabolomic investigation of astrocytes interacted with Abeta(42) or its complexes with either copper(II) or zinc(II), J. Inorg. Biochem, 117, 326, 10.1016/j.jinorgbio.2012.08.021 · DOI
- Rukhsana, 2010, Role of oxidative stress in the progression of Alzheimer’s disease, J. Alzheimers Dis, 19, 341, 10.3233/JAD-2010-1222 · DOI · Paper page
- Wu, 2005, The human pineal gland and melatonin in aging and Alzheimer’s disease, J. Pineal Res, 38, 145, 10.1111/j.1600-079X.2004.00196.x · DOI · Paper page
- Wu, 2003, Molecular changes underlying reduced pineal melatonin levels in Alzheimer’s disease: Alterations in preclinical and clinical stages, J. Clin. Endocr. Metab, 88, 5898, 10.1210/jc.2003-030833 · DOI · Paper page
- Ferrari, 2000, Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia, Exp. Gerontol, 35, 1239, 10.1016/S0531-5565(00)00160-1 · DOI
- Ohashi, 1999, Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type, Biol. Psychiat, 45, 1646, 10.1016/S0006-3223(98)00255-8 · DOI
- Liu, 1999, Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype, J. Clin. Endocr. Metab, 84, 323
- Zhou, 2003, Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels, J. Pineal Res, 35, 125, 10.1034/j.1600-079X.2003.00065.x · DOI · Paper page
- Savaskan, 2002, Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer’s disease patients, J. Pineal Res, 32, 59, 10.1034/j.1600-079x.2002.00841.x · DOI
- Savaskan, 2005, Reduced hippocampal MT2 melatonin receptor expression in Alzheimer’s disease, J. Pineal Res, 38, 10, 10.1111/j.1600-079X.2004.00169.x · DOI · Paper page
- Friedland, 1990, A quantitative study of intracranial calcification in dementia of the Alzheimer’s type, Int. Psychogeriatr, 2, 36, 10.1017/S104161029000028X · DOI
- Wu, 2007, A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer’s disease patients, Brain Res, 1167, 13, 10.1016/j.brainres.2007.06.053 · DOI
- Garfinkel, 2000, Melatonin for treatment of sundowning in elderly persons with dementia—A preliminary study, Arch. Gerontol. Geriatr, 31, 65, 10.1016/S0167-4943(00)00068-6 · DOI · Paper page
- Brusco, 2000, Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease, Neuro Endocrinol. Lett, 21, 39
- Brusco, 1998, Monozygotic twins with Alzheimer’s disease treated with melatonin: Case report, J. Pineal Res, 25, 260, 10.1111/j.1600-079X.1998.tb00396.x · DOI · Paper page
- Cardinali, 2002, Melatonin in sleep disorders and jet-lag, Neuro Endocrinol. Lett, 23, 9
- Cardinali, 2002, The use of melatonin in Alzheimer’s disease, Neuro Endocrinol. Lett, 23, 20
- Karasek, 2002, Future of melatonin as a therapeutic agent, Neuro Endocrinol. Lett, 23, 118
- Singer, 2003, Alzheimer’s disease cooperative, SA multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease, Sleep, 26, 893, 10.1093/sleep/26.7.893 · DOI · Paper page
- Ling, 2009, Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin, J. Alzheimers Dis, 16, 287, 10.3233/JAD-2009-0949 · DOI
- Brion, 2001, Neurofibrillary tangles and tau phosphorylation, Biochem. Soc. Symp, 67, 81, 10.1042/bss0670081 · DOI
- Billingsley, 1997, Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration, Biochem. J, 323, 577, 10.1042/bj3230577 · DOI · Paper page
- Braak, 1994, A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads, Acta Neuropathol, 87, 554, 10.1007/BF00293315 · DOI · Paper page
- Avila, 2004, Assembly in vitro of tau protein and its implications in Alzheimer’s disease, Curr. Alzheimer’s Res, 1, 97, 10.2174/1567205043332207 · DOI
- Sahara, 2013, Characteristics of TBS-extractable hyperphosphorylated Tau species: Aggregation intermediates in rTg4510 mouse brain, J. Alzheimers Dis, 33, 249, 10.3233/JAD-2012-121093 · DOI
- Khatoon, 1992, Brain levels of microtubule-associated protein tau are elevated in Alzheimer’s disease: A radioimmuno-slot-blot assay for nanograms of the protein, J. Neurochem, 59, 750, 10.1111/j.1471-4159.1992.tb09432.x · DOI · Paper page
- Khatoon, 1994, Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer’s disease and control brains, FEBS Lett, 351, 80, 10.1016/0014-5793(94)00829-9 · DOI · Paper page
- Hanger, 1998, New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer’s disease brain using nanoelectrospray mass spectrometry, J. Neurochem, 71, 2465, 10.1046/j.1471-4159.1998.71062465.x · DOI · Paper page
- Hasegawa, 1995, Hyperphosphorylation of tau in PHF, Neurobiol. Aging, 16, 365, 10.1016/0197-4580(95)00027-C · DOI · Paper page
- Wang, 2008, Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro, Mol. Cell. Biochem., 310, 49, 10.1007/s11010-007-9664-6 · DOI
- Peng, 2013, Disease-modified glycogen synthase kinase-3beta intervention by melatonin arrests the pathology and memory deficits in an Alzheimer’s animal model, Neurobiol. Aging, 34, 1555, 10.1016/j.neurobiolaging.2012.12.010 · DOI
- Deng, 2005, Effects of melatonin on wortmannin-induced tau hyperphosphorylation, Acta Pharmacol. Sin, 26, 519, 10.1111/j.1745-7254.2005.00102.x · DOI
- Li, 2005, Effect of melatonin on calyculin A-induced tau hyperphosphorylation, Eur. J. Pharmacol, 510, 25, 10.1016/j.ejphar.2005.01.023 · DOI
- Li, 2004, Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity, J. Pineal Res, 36, 186, 10.1111/j.1600-079X.2004.00116.x · DOI
- Yang, 2011, Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A, J. Psychopharmacol, 25, 1118, 10.1177/0269881110367723 · DOI
- Wang, 2004, Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions, Acta Pharmacol. Sin, 25, 276
- Liu, 2002, Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin, Acta Pharmacol. Sin, 23, 183
- Wang, 2004, Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain, J. Pineal Res, 37, 11, 10.1111/j.1600-079X.2004.00130.x · DOI
- Wang, 2005, Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat, Acta Pharmacol. Sin, 57, 7
- Avila, 2000, Tau aggregation into fibrillar polymers: Taupathies, FEBS Lett, 476, 89, 10.1016/S0014-5793(00)01676-8 · DOI
- Zhu, 2004, Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat, J. Pineal Res, 37, 71, 10.1111/j.1600-079X.2004.00136.x · DOI
- Reiter, 2001, Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system, Ann. N. Y. Acad. Sci, 939, 200, 10.1111/j.1749-6632.2001.tb03627.x · DOI · Paper page
- Smith, 2003, Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells, J. Neurosci. Res, 71, 863, 10.1002/jnr.10525 · DOI
- Lovell, 2004, Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3, J. Alzheimers Dis, 6, 659, 10.3233/JAD-2004-6610 · DOI · Paper page
- Kenyon, 2010, The genetics of ageing, Nature, 464, 504, 10.1038/nature08980 · DOI · Paper page
- Paradies, 2010, Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease, J. Pineal Res, 48, 297, 10.1111/j.1600-079X.2010.00759.x · DOI · Paper page
- Romero, 2010, Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells, J. Pineal Res, 49, 141, 10.1111/j.1600-079X.2010.00778.x · DOI
- Hardeland, 2009, Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines, J. Pineal Res, 47, 109, 10.1111/j.1600-079X.2009.00701.x · DOI · Paper page
- Jou, 2010, Visualization of melatonin’s multiple mitochondrial levels of protection against mitochondrial Ca(2+)-mediated permeability transition and beyond in rat brain astrocytes, J. Pineal Res, 48, 20, 10.1111/j.1600-079X.2009.00721.x · DOI · Paper page
- Hong, 2010, Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury, J. Pineal Res, 49, 201, 10.1111/j.1600-079X.2010.00786.x · DOI
- Das, 2010, The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors, J. Pineal Res, 48, 157, 10.1111/j.1600-079X.2009.00739.x · DOI
- Schuster, 2005, The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway, J. Neuroendocrinol, 17, 170, 10.1111/j.1365-2826.2005.01288.x · DOI
- Peschke, 2002, Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1, J. Pineal Res, 33, 63, 10.1034/j.1600-079X.2002.02919.x · DOI
- MacKenzie, 2000, Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mt1 melatonin receptor, Cell Motil. Cytoskeleton, 46, 28, 10.1002/(SICI)1097-0169(200005)46:1<28::AID-CM4>3.0.CO;2-5 · doi:10.1002/(sici)1097-0169(200005)46:1<28::aid-cm4>3.0.co;2-5
- Gerdin, 2003, Regulation of basal rhythmicity in protein kinase C activity by melatonin in immortalized rat suprachiasmatic nucleus cells, Neurosci. Lett, 346, 37, 10.1016/S0304-3940(03)00590-1 · DOI
- Rios, 1996, In vitro inhibition of Ca2+/calmodulin-dependent kinase II activity by melatonin, Biochim. Biophys. Acta, 1290, 191, 10.1016/0304-4165(96)00025-6 · DOI
- Chen, 2011, CaMKII is involved in cadmium activation of MAPK and mTOR pathways leading to neuronal cell death, J. Neurochem, 119, 1108, 10.1111/j.1471-4159.2011.07493.x · DOI
- Chan, 2002, Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins, Cell. Signal, 14, 249, 10.1016/S0898-6568(01)00240-6 · DOI
- Chen, 2011, Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death, Free Radic. Biol. Med, 50, 624, 10.1016/j.freeradbiomed.2010.12.032 · DOI · Paper page
- Xu, 2011, Calcium signaling is involved in cadmium-induced neuronal apoptosis via induction of reactive oxygen species and activation of MAPK/mTOR network, PLoS One, 6, e19052, 10.1371/journal.pone.0019052 · DOI · Paper page
- Selkoe, 1998, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease, Trends Cell Biol, 8, 447, 10.1016/S0962-8924(98)01363-4 · DOI · Paper page
- Fisher, 2003, M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: Implications in future therapy, J. Mol. Neurosci, 20, 349, 10.1385/JMN:20:3:349 · DOI
- Lahiri, 1999, Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types, J. Pineal Res, 26, 137, 10.1111/j.1600-079X.1999.tb00575.x · DOI
- Matsubara, 2003, Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease, J. Neurochem, 85, 1101, 10.1046/j.1471-4159.2003.01654.x · DOI · Paper page
- Lahiri, 2004, Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex, J. Pineal Res, 36, 224, 10.1111/j.1600-079X.2004.00121.x · DOI
- Song, 1997, Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12, J. Mol. Neurosci, 9, 75, 10.1007/BF02736852 · DOI
- Zhang, 2004, Melatonin attenuates beta-amyloidinduced inhibition of neurofilament expression, Acta Pharmacol. Sin, 25, 447
- Olivieri, 2001, Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion, J. Pineal Res, 31, 320, 10.1034/j.1600-079X.2001.310406.x · DOI
- Wang, 2008, Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells, Neurochem. Res, 33, 1138, 10.1007/s11064-007-9563-y · DOI
- Quinn, 2005, Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials, Brain Res, 1037, 209, 10.1016/j.brainres.2005.01.023 · DOI
- Hsiao, 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
- Su, 2004, Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing, Biochemistry, 43, 6899, 10.1021/bi035627j · DOI · Paper page
- Ryder, 2003, Divergent roles of GSK-3 and CDK5 in APP processing, Biochem. Biophys. Res. Commun, 312, 922, 10.1016/j.bbrc.2003.11.014 · DOI
- Phiel, 2003, GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides, Nature, 423, 435, 10.1038/nature01640 · DOI · Paper page
- Donnelly, 2008, Selective intracellular release of copper and zinc ions from bis (thiosemicarbazonato) complexes reduces levels of Alzheimer’s disease amyloid-beta peptide, J. Biol. Chem, 283, 4568, 10.1074/jbc.M705957200 · DOI · Paper page
- Tesco, 2000, GSK-3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations, Ann. N. Y. Acad. Sci, 920, 227, 10.1111/j.1749-6632.2000.tb06927.x · DOI
- Takashima, 1998, Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau, Proc. Natl. Acad. Sci. USA, 95, 9637, 10.1073/pnas.95.16.9637 · DOI · Paper page
- Simmons, 1994, Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro, Mol. Pharmacol, 45, 373
- Soto, 1996, The conformation of Alzheimer’s beta peptide determines the rate of amyloid formation and its resistance to proteolysis, Biochem. J, 314, 701, 10.1042/bj3140701 · DOI
- Poeggeler, 2001, Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer’s amyloid Abeta peptide, Biochemistry, 40, 14995, 10.1021/bi0114269 · DOI
- Skribanek, 2001, Interaction between synthetic amyloid-beta-peptide (1–40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry, J. Mass Spectrom, 36, 1226, 10.1002/jms.243 · DOI
- Pappolla, 1998, Inhibition of Alzheimer’s beta-fibrillogenesis by melatonin, J. Biol. Chem, 273, 7185, 10.1074/jbc.273.13.7185 · DOI · Paper page
- Huang, 1997, Fibrillogenesis of Alzheimer’s Abeta peptides studied by fluorescence energy transfer, J. Mol. Biol, 269, 214, 10.1006/jmbi.1997.1050 · DOI
- Fraser, 1991, pH-dependent structural transitions of Alzheimer’s amyloid peptides, Biophys. J, 60, 1190, 10.1016/S0006-3495(91)82154-3 · DOI · Paper page
- Masilamoni, 2008, The neuroprotective role of melatonin against amyloid beta peptide injected mice, Free Radic. Res, 42, 661, 10.1080/10715760802277388 · DOI
- Pacchierotti, 2001, Melatonin in psychiatric disorders: A review on the melatonin involvement in psychiatry, Front. Neuroendocrin, 22, 18, 10.1006/frne.2000.0202 · DOI · Paper page
- Yuan, 1991, [125I]Iodomelatonin-binding sites in the pigeon brain: Binding characteristics, regional distribution and diurnal variation, J. Endocrinol., 128, 475, 10.1677/joe.0.1280475 · doi:10.1677/joe.0.1280475
- Bieschke, 2005, Oxidative metabolites accelerate Alzheimer’s amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation, Biochemistry, 44, 4977, 10.1021/bi0501030 · DOI
- Feng, 2004, Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism, Free Radic. Biol. Med, 37, 1790, 10.1016/j.freeradbiomed.2004.08.023 · DOI
- Zatta, 2003, Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metalions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)], J. Pineal Res, 35, 98, 10.1034/j.1600-079X.2003.00058.x · DOI
- Feng, 2004, Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer’s disease, J. Pineal Res, 37, 129, 10.1111/j.1600-079X.2004.00144.x · DOI · Paper page
- Shen, 2002, The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25–35 in middle-aged rats, J. Pineal Res, 32, 85, 10.1034/j.1600-079x.2002.1819.x · DOI
- Tan, 2003, Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E, J. Pineal Res, 35, 80, 10.1034/j.1600-079X.2003.00057.x · DOI
- Slats, 2013, Reciprocal interactions between sleep, circadian rhythms and Alzheimer’s disease: Focus on the role of hypocretin and melatonin, Ageing Res. Rev, 12, 188, 10.1016/j.arr.2012.04.003 · DOI
- Rothman, 2012, Sleep disturbances in Alzheimer’s and Parkinson’s diseases, Neuromolecular Med, 14, 194, 10.1007/s12017-012-8181-2 · DOI · Paper page
- Cecon, 2011, Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders, Recent Pat. Endocr. Metab. Immune Drug Discov, 5, 91, 10.2174/187221411799015381 · doi:10.2174/187221411799015381
- Kang, 2009, Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle, Science, 326, 1005, 10.1126/science.1180962 · DOI · Paper page
- Struble, 1982, Cholinergic innervation in neuritic plaques, Science, 216, 413, 10.1126/science.6803359 · DOI · Paper page
- Coyle, 1983, Alzheimer’s disease: A disorder of cortical cholinergic innervation, Science, 219, 1184, 10.1126/science.6338589 · DOI · Paper page
- Rasool, 1986, Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer’s disease, Ann. Neurol, 20, 482, 10.1002/ana.410200407 · DOI
- Samuel, 1994, Hippocampal connectivity and Alzheimer’s dementia: Effects of synapse loss and tangle frequency in a two-component model, Neurology, 44, 2081, 10.1212/WNL.44.11.2081 · DOI
- Davis, 1999, Cholinergic markers in elderly patients with early signs of Alzheimer’s disease, J. Am. Med. Assoc, 281, 1401, 10.1001/jama.281.15.1401 · DOI · Paper page
- Rinne, 2003, Semantic decision making in early probable AD: A PET activation study, Cogn. Brain Res, 18, 89, 10.1016/j.cogbrainres.2003.09.009 · DOI
- Terry, 2003, The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development, J. Pharmacol. Exp. Ther., 306, 821, 10.1124/jpet.102.041616 · DOI · Paper page
- Spencer, 2010, Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slices, Neuropharmacology, 59, 437, 10.1016/j.neuropharm.2010.06.005 · DOI
- Guermonprez, 2001, Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite are differentially prevented by antioxidants, Mol. Pharmacol, 60, 838
- Feng, 2004, Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats, J. Pineal Res, 37, 198, 10.1111/j.1600-079X.2004.00158.x · DOI
- Tang, 2002, The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1–40, Life Sci, 71, 2625, 10.1016/S0024-3205(02)02105-7 · DOI
- Agrawal, 2009, A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia, Neuropharmacology, 56, 779, 10.1016/j.neuropharm.2009.01.005 · DOI · Paper page
- Hansen, 2008, Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis, Clin. Interv. Aging, 3, 211
- Cardinali, 2010, Clinical aspects of melatonin intervention in Alzheimer’s disease progression, Curr. Neuropharmacol, 8, 218, 10.2174/157015910792246209 · DOI · Paper page
- Perez, 2009, Tacrine-melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties, ChemMedChem, 4, 828, 10.1002/cmdc.200800414 · DOI · Paper page
- Spuch, 2010, A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer’s disease, Neurotox. Res, 17, 421, 10.1007/s12640-009-9121-2 · DOI
- Arends, 2000, Microglia, amyloid and dementia in Alzheimer’s disease. A correlative study, Neurobiol. Aging, 21, 39, 10.1016/S0197-4580(00)00094-4 · DOI · Paper page
- Stuchbury, 2005, Alzheimer’s associated inflammation, potential drug targets and future therapies, J. Neural. Transm, 112, 429, 10.1007/s00702-004-0188-x · DOI
- Tuppo, 2005, The role of inflammation in Alzheimer’s disease, Int. J. Biochem. Cell B, 37, 289, 10.1016/j.biocel.2004.07.009 · DOI · Paper page
- Park, 2012, Anti-inflammatory effects of aromatic-turmerone through blocking of NF-kappaB, JNK, and p38 MAPK signaling pathways in amyloid beta-stimulated microglia, Int. Immunopharmacol, 14, 13, 10.1016/j.intimp.2012.06.003 · DOI
- Chung, 2003, Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition, J. Pineal Res, 34, 95, 10.1034/j.1600-079X.2003.00010.x · DOI
- Mohan, 1995, The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B, Biochem. Mol. Biol. Int, 37, 1063
- Chuang, 1996, Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen, Cell Biol. Int, 20, 687, 10.1006/cbir.1996.0091 · DOI
- Lau, 2012, Interleukin-6 autocrine signaling mediates melatonin MT(1/2) receptor-induced STAT3 Tyr(705) phosphorylation, J. Pineal Res, 52, 477, 10.1111/j.1600-079X.2011.00965.x · DOI
- Shen, 2007, Suppressive effects of melatonin on amyloid-beta-induced glial activation in rat hippocampus, Arch. Med. Res, 38, 284, 10.1016/j.arcmed.2006.10.007 · DOI
- Grases, 2010, A potential role for crystallization inhibitors in treatment of Alzheimer’s disease, Med. Hypoth, 74, 118, 10.1016/j.mehy.2009.07.029 · DOI
- Wollen, 2010, Alzheimer’s disease: The pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners, J. Clin. Ther, 15, 223
- Dowling, 2008, Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease, J. Am. Geriatr. Soc, 56, 239, 10.1111/j.1532-5415.2007.01543.x · DOI · Paper page
- Pappolla, 2000, An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for Alzheimer’s disease, J. Neural. Transm, 107, 203, 10.1007/s007020050018 · DOI · Paper page
- Nagtegaal, 1996, Melatonin: A survey of suspected adverse drug reactions, Sleep-Wake Res. Netherl, 7, 115
- Avery, 1998, Guidelines for prescribing melatonin, Ann. Med, 30, 122, 10.3109/07853899808999394 · DOI
Cited by
Peter-Derex, L., Yammine, P., Bastuji, H., & Croisile, B. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.03.007 · Cited by 453
'The clocks that time us'—circadian rhythms in neurodegenerative disorders
Videnovic, A., Lazar, A. S., Barker, R. A., & Overeem, S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.206 · Cited by 373
Melatonin and its metabolites vs oxidative stress: From individual actions to collective protection
Galano, A., & Reiter, R. J. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12514 · Cited by 353
Aging, melatonin, and the pro- and anti-inflammatory networks
Hardeland, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051223 · Cited by 337
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Metadata
- Authors
- Lin, L., Huang, Q.-X., Yang, S.-S., Chu, J., Wang, J.-Z., & Tian, Q.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-07-12
- Volume
- 14
- Issue
- 7
- Pages
- 14575-14593
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2162142126
- Cited by
- 215
- References
- 13
- FWCI
- 13.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Melatonin in Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/ijms140714575
- The paper
- Lin, L., Huang, Q.-X., Yang, S.-S., Chu, J., Wang, J.-Z., & Tian, Q. (2013). Melatonin in Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms140714575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.